Rosanne Michie of Optometry Austrialia reviews Okogen’s upcoming Australian trial that aims to fill the absence of approved therapies to treat the underlying cause of viral conjunctivitis.
Rosanne Michie of Optometry Austrialia reviews Okogen’s upcoming Australian trial that aims to fill the absence of approved therapies to treat the underlying cause of viral conjunctivitis.
© $year Okogen, Inc. All Rights Reserved
United States
Okogen, Inc.
8400 Belleview Drive, Suite 125
Plano, Texas 75024
USA
Australia
Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000
AUS
